Samuel del Rio, MD
Gynecology · Merritt Island, FLNPI 1265497663
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (59.3%), consulting fees and education — rather than concentrated in one kind of arrangement. 21 manufacturers reported payments, led by Dysis Medical, Inc. at 35.3% of the total. Reporting peaked in 2021 at $1,256 and has fallen 95.7% since, to $55 in 2025.
Across 106 payments — averaging $29.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Dysis Medical, Inc.$1K
- Astellas Pharma US Inc$579
- AbbVie$253
- Radius Health, Inc.$190
- Millicent US Inc$189
- Pfizer$112
- plus $691 from 15 others
What the payments were for
- Consulting fees$1,07535%
- Food & beverage$1,84659%
- Education$1946%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Dysis Medical, Inc. | 5 | $1,100 |
| Astellas Pharma US Inc | 30 | $579 |
| AbbVie(2 entities) | 13 | $253 |
| Radius Health, Inc. | 9 | $190 |
| Millicent US Inc | 11 | $189 |
| Pfizer | 6 | $112 |
| Sumitomo Pharma America, Inc. | 6 | $110 |
| Hologic Sales And Service, LLC | 6 | $109 |
| Intuitive Surgical | 1 | $86 |
| Mayne Pharma Commercial LLC | 3 | $77 |
| Therapeuticsmd, Inc. | 4 | $76 |
| Aspira Women's Health Inc | 2 | $59 |
| Exact Sciences | 2 | $39 |
| Lupin Inc. | 1 | $22 |
| Evofem Biosciences, Inc. | 1 | $21 |
| Daiichi Sankyo Inc. | 1 | $21 |
| Medtronic | 1 | $18 |
| Urovant Sciences Inc | 1 | $16 |
| Agile Therapeutics, Inc. | 1 | $15 |
| Exeltis, USA Inc. | 1 | $12 |
| Avion Pharmaceuticals | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DYSIS v3 Digital Coploscope$2,325
- DYSIS Ultra$775
- DYSIS Ultra 2.0$775
- Ultra 2.0$300
How this compares
$3,115 in reported general payments places this provider in the 80th percentile of 290 gynecology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 100 | $110,536 |
| GemtesaVibegron | 68 | $72,089 |
| PremarinEstrogens, Conjugated | 19 | $9,257 |
| Estradiol | 151 | $8,024 |
| Solifenacin Succinate | 59 | $4,693 |
| Raloxifene Hcl | 48 | $3,490 |
| Tolterodine Tartrate ErTolterodine Tartrate | 14 | $1,280 |
| Trospium Chloride | 11 | $1,022 |
| ValacyclovirValacyclovir Hcl | 13 | $873 |
| Ibandronate Sodium | 22 | $689 |
| Metronidazole | 16 | $567 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 37 | $525 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 21 | $199 |
| Alendronate Sodium | 14 | $168 |
| Fluconazole | 20 | $152 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $579 | $110,536100 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $110 | $72,08968 claims |
| PfizerPremarin | $112 | $9,25719 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 290 gynecology providers in Florida.
Other gynecology in Merritt Island
- Janie GeraciMerritt Island$3K
- Aileen CaceresKissimmee$406K
- Parveen VahoraNew Port Richey$327K
- James KondrupVenice$310K
- Andrea GallowayThe Villages$252K
- Jessica VaughtOrlando$129K
- Steven ChavoustieMiami$113K
- Marshall BovelskyMelbourne$52K
- Minda NeimarkFt Lauderdale$46K
- Meenakshi JainSt Petersburg$35K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.